通过CD137合酶-shRNA仿真体准瘤内调节性T细胞
Kang Yi Lee1,2,3, Yu Mei1,2,3, Haiyan Liu1,2,3
1NUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore, Singapore.
CD137的阿巴-shRNA仿真体针对CD137的恶性细胞和调节性T细胞 (Tregs). 这种新的方法显示了癌症免疫治疗的潜力,通过降低瘤细胞和Tregs中的关键基因的下调.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- CD137 (4-1BB) 是一种T细胞共刺激分子,参与免疫调节.
- 调节性T细胞 (Tregs) 在负反循环中利用CD137来防止自身免疫损伤.
- 内Tregs上的CD137表达与癌症患者的预后不佳相关,并且也在恶性细胞上发现.
研究的目的:
- 研究CD137作为癌症免疫治疗中的治疗标.
- 开发用于癌症治疗的新型CD137向剂.
主要方法:
- 开发一种CD137特异性胺酶,能够被CD137表达细胞结合和内化.
- CD137合酶与短毛RNAs (shRNAs) 融合,这些RNAs向Zeste同源2 (EzH2) 或神经平素-1 (Nrp1) 的增强剂.
主要成果:
- CD137胺酶成功结合并被恶性细胞和表达CD137.7的T细胞内部化.
- 这种CD137胺-shRNA仿真体有效地降低了CD137阳性恶性细胞和Tregs中的EzH2和Nrp1的下调.
- CD137表达区分了内口和外口Tregs,CD137+Tregs具有更强的免疫抑制作用.
结论:
- CD137是瘤免疫治疗的验证标.
- CD137 体-shRNA 嵌合体代表了癌症治疗治疗工具的有前途的新类治疗工具.
更多相关视频
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
03:38Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
Published on: October 6, 2022
相关概念视频
Cis-regulatory Sequences
Cis-regulatory Sequences
Global Regulatory Systems
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Drug Control Governance: Regulatory Bodies and Their Impact
Targeted Cancer Therapies
There are several types of targeted therapies against...
